The Bio/Pharma Beat

    View Author April 2020

    In this “stay-at-home” edition, we highlight the patent law developments you should know in biotech, biologics and pharmaceutical cases, legislation and federal agency actions from March 2020, including:

    • The Federal Circuit reverses two district court decisions holding method of treatment and method of preparing claims patent ineligible
    • The Federal Circuit finds that clearly limiting statements during prosecution did not create prosecution history estoppel when the PTO rejected those prosecution arguments
    • A district court denies JMOL and upholds a US $752 million jury award and a 27% running royalty